IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
NCT06451198
Summary
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.
Eligibility
Inclusion Criteria: * Age over 65 years old * Diagnosed with acute coronary syndrome (unstable angina/ non-ST elevation myocardial infarction/ ST elevation myocardial infarction) * Treated with at least 1 DES implanted in the coronary lesion * Receiving dual antiplatelet therapy (aspirin plus ticagrelor) * Agree to attend the trial Exclusion Criteria: * Elective surgical procedure planned within 12 months * Life expectancy ≤1 year * Known allergy or intolerance to aspirin, ticagrelor or nonsteroidal anti-inflammatory drugs (NSAIDs) * History of cerebral hemorrhage * History of stroke in six months * Active bleeding * Known relevant hematological deviations * Known, clinically important thrombocytopenia (i.e., \<100\*10\^9/L) or anemia (i.e., \<90g/L) * Active cancer * Concomitant use of oral anticoagulants * Active participation in another clinical study * Other situations in which the investigator considers unsuitable to attend the study
Conditions3
Interventions3
Related trials
- ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography — Jung-min Ahn
- Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention — Peking Union Medical College Hospital
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes — Montreal Heart Institute
- Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization — Takeshi Morimoto
- Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation — Insel Gruppe AG, University Hospital Bern
- Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation — Kyoto University
- Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer — Centre Hospitalier Universitaire de Besancon
- Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage — Radboud University Medical Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06451198